Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 5
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
EGFR exon 19 deletion
gastric cancer · Therapy Not Normalized
EGFR exon 19 deletion is flagged as trial selection rising because public trials show inclusion required evidence in 7 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 2
Common snippets: dMMR | BRAF V600E
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Medium
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT04117958 | https://clinicaltrials.gov/study/NCT06075849 | https://clinicaltrials.gov/study/NCT05563766 | https://clinicaltrials.gov/study/NCT07333820 | https://clinicaltrials.gov/study/NCT05625737 | https://clinicaltrials.gov/study/NCT04260191 | https://clinicaltrials.gov/study/NCT05583201